Treatment of Squamous Cell Carcinoma
For localized cutaneous squamous cell carcinoma (cSCC), surgical excision with histologically confirmed negative margins is the definitive treatment, while for advanced/metastatic disease, anti-PD-1 immunotherapy (cemiplimab or pembrolizumab) is now the first-line systemic therapy.
Primary Localized Disease
Low-Risk Tumors
Standard surgical excision with 4-6 mm clinical margins extending to mid-subcutaneous fat is recommended for low-risk primary cSCC 1. This achieves approximately 95% clearance rates with an average local recurrence rate of 5.4% 1. The excision must include histologic margin assessment using "bread loaf" sectioning to confirm negative margins.
High-Risk Tumors
Mohs micrographic surgery (MMS) is the preferred approach for high-risk cSCC, providing complete peripheral and deep margin control while maximizing tissue conservation 1. High-risk features include:
- Tumors >2 cm diameter
- Poor differentiation
- Perineural invasion
- Depth >4 mm or invasion beyond subcutaneous fat
- Recurrent tumors
- Location on high-risk anatomic sites (ears, lips, temples)
- Immunosuppressed patients
For high-risk tumors requiring standard excision, at least 6-mm margins are necessary to achieve 95% clearance 1.
Margin Management
If margins are positive after excision, re-excision is mandatory for operable cases 2. Delay complex reconstructions until negative margins are histologically confirmed 1.
Head and Neck Mucosal SCC
For locally advanced head and neck squamous cell carcinoma (HNSCC), the treatment paradigm differs significantly:
Resectable Disease
Surgery followed by adjuvant radiotherapy remains standard, with chemoradiotherapy (cisplatin-based) added for high-risk features 3. Recent evidence shows perioperative pembrolizumab added to surgery and RT/CRT improves event-free survival 4.
Recurrent/Metastatic HNSCC
First-line treatment is pembrolizumab plus chemotherapy (cisplatin or carboplatin + 5-FU), which improved overall survival to 13 months versus 10.7 months with the previous standard (EXTREME regimen) 3.
Alternatively, pembrolizumab monotherapy is appropriate for PD-L1 positive tumors (CPS ≥1), particularly when rapid tumor shrinkage is not urgently needed, with median OS of 12.3-14.9 months depending on PD-L1 expression 3. However, this approach has lower response rates (19-23%) and shorter progression-free survival (3.2-3.4 months) compared to combination therapy.
Advanced Cutaneous SCC
Locally Advanced or Metastatic Disease
Anti-PD-1 immunotherapy is the first-line systemic treatment for patients with locally advanced cSCC (laCSCC) or metastatic cSCC (mCSCC) not amenable to curative surgery or radiation 1, 2:
- Cemiplimab: FDA/EMA approved as the first systemic agent for advanced cSCC
- Pembrolizumab: Also approved with growing evidence for efficacy
These agents represent a paradigm shift from the previous reliance on chemotherapy or EGFR inhibitors.
Regional Metastases
For operable regional lymph node metastases, perform therapeutic lymph node dissection followed by consideration of adjuvant radiation therapy 1, 2.
For inoperable regional disease, combination chemoradiation therapy should be considered 1.
Second-Line Options
If immunotherapy fails or is contraindicated, EGFR inhibitors (cetuximab or panitumumab) combined with chemotherapy or radiation are second-line options 1, 2.
Non-Surgical Modalities
Radiation Therapy
Primary radiation therapy is appropriate when surgery is contraindicated, not feasible, or declined by the patient after informed discussion 1. Smaller, thinner tumors respond better. Adjuvant radiation should be considered for high-risk features including perineural invasion after surgical treatment 1.
Modalities to Avoid for Invasive cSCC
- Cryosurgery: Only for low-risk lesions when more effective therapies are contraindicated, due to lack of margin control 1
- Topical therapies (imiquimod, 5-FU): Not supported by evidence for invasive cSCC 1
- Photodynamic therapy (PDT): Insufficient evidence; may even induce well-differentiated cSCC 1
- Laser treatment: Extremely limited data, not recommended 1
Special Populations
Immunosuppressed Patients (Solid Organ Transplant Recipients)
These patients have 2-3 times higher metastatic risk 1. Consider:
- Dose reduction of immunosuppressive agents when appropriate
- Switch from calcineurin inhibitors to mTOR inhibitors (sirolimus), though recent evidence questions efficacy 1
- Mandatory multidisciplinary consultation for advanced disease
Critical Management Principles
Multidisciplinary tumor board evaluation is mandatory for all patients with advanced disease requiring more than surgery 2. This includes surgical oncology, medical oncology, radiation oncology, and dermatology.
Sentinel lymph node biopsy (SLNB) can detect occult metastases in high-risk localized tumors, but its impact on management and outcomes remains uncertain 1.
Best supportive and palliative care should be provided to optimize symptom management and quality of life in advanced disease 1, 2.
Common Pitfalls
- Inadequate margins: Using <4 mm margins for low-risk or <6 mm for high-risk tumors increases recurrence risk
- Delayed reconstruction: Performing complex repairs before confirming negative margins may necessitate additional surgery
- Overlooking high-risk features: Failure to identify perineural invasion, poor differentiation, or depth of invasion leads to undertreatment
- Using non-surgical modalities for high-risk disease: Cryotherapy, topicals, or PDT lack margin control and are inappropriate for invasive cSCC
- Missing immunosuppression status: Transplant recipients require modified treatment approaches and closer surveillance